Investor Overview

Company Profile
We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.
Stock Quote
XENE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.90
Change (%)0.00 (0.00%)
Volume0
Data as of December 7, 2016 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
November 8, 2016 – 4:03 p.m.
Xenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
Upcoming EventsMore >>
There are currently no events scheduled.
What's New
Download Documentation 2015 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Xenon Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources